Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.